Evidence map›Paper›PMID 30887312›Full record

ReviewSports medicine (Auckland, N.Z.)2019

Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.

Hayden Allen, Susan H Backhouse, James H Hull, Oliver J Price

Open access · hybridAbstract readReview
In one paragraph

Review in Sports medicine (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Salbutamol in the Management of Asthma: A Review.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hayden AllenCarnegie School of Sport, Leeds Beckett University, Leeds, LS6 3QT, UK.
Susan H BackhouseCarnegie School of Sport, Leeds Beckett University, Leeds, LS6 3QT, UK.ORCID http://orcid.org/0000-0002-4810-5173
James H HullDepartment of Respiratory Medicine, Royal Brompton Hospital, London, UK.ORCID http://orcid.org/0000-0003-4697-1526
Oliver J PriceCarnegie School of Sport, Leeds Beckett University, Leeds, LS6 3QT, UK. o.price@leedsbeckett.ac.uk.ORCID http://orcid.org/0000-0001-8596-4949
Leeds Beckett University · GBRoyal Brompton Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is prevalent in athletes and when untreated can impact both respiratory health and sports performance. Pharmacological inhaler therapy currently forms the mainstay of treatment; however, for elite athletes competing under the constraints of the World Anti-Doping Code (Code), a number of established therapies are prohibited both in and/or out of competition and/or have a maximum permitted dose. The recent release of medical information detailing inhaler therapy in high-profile athletes has brought the legitimacy and utilisation of asthma medication in this setting into sharp focus. This narrative review critically appraises recent changes to anti-doping policy and the Code in the context of asthma management, evaluates the impact of asthma medication use on sports performance and employs a theory of behaviour to examine perceived determinants and barriers to athletes adhering to the anti-doping rules of sport when applied to asthma.

Indexed as

AthletesAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAlbuterolAsthmaBronchodilator AgentsDoping in SportsFormoterol FumarateHumansNebulizers and VaporizersPerformance-Enhancing SubstancesSalmeterol XinafoateSportsAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAlbuterolBronchodilator AgentsFormoterol FumaratePerformance-Enhancing SubstancesSalmeterol Xinafoate

Identifiers

PMID30887312
PMCPMC6459780
OpenAlexW2921813825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.